Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-platelet membrane glycoprotein vi monoclonal antibody

Inactive Publication Date: 2009-02-12
MOCHIDA PHARM CO LTD
View PDF1 Cites 79 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0038]The twelfth embodiment is a method of manufacturing an antibody specific for GPVI, which is characterized by using the peptide of the eighth embodiment or the polypeptide of the ninth embodiment, specifically,(34) a method of manufacturing an antibody specific for GPVI, preferably the antibody of the first to the third embodiments of the present invention, which is characterized by using the peptide of the eighth embodiment or the polypeptide of the ninth embodiment as an antigen for immunization or as an antigen for in vitro immunization;(35) a method of manufacturing an antibody specific for GPVI, preferably the antibody of the first to the third embodiments of the present invention, which is characterized by using the peptide of the eighth embodiment or the polypeptide of the ninth embodiment as an antigen for detection or identification of the antibody. That is, using a recombinant GPVI as an immunogen and / or an antigen for detection, wherein the amino acid sequence on human GPVI, such as the amino acid sequence corresponding to the loop structure, which can be recognized by the antibody of the present invention, is integrated into mouse GPVI, a novel antibody which can recognize the same recognition region can be obtained. As a more preferred method of preparing an antibody for human therapy, the method using human antibody gene-transgenic non-human animal has been disclosed (WO 2002 / 070648 (Tokuhyou 2005-504507) and WO 2002 / 043478 (Tokuhyou 2004-515230)). When using a protein, wherein a partial amino acid sequence of human GPVI is integrated into a heterogeneous GPVI, for example, mouse GPVI, the above-mentioned transgenic animal such as a mouse is immunized, it will be considered that a human antibody which reacts with the integrated amino acid sequence from human, preferably epitope, but not the amino acid sequence from mouse on GPVI can be obtained efficiently. Therefore, the human antibody obtained by such method is useful as a human antibody having the features of the antibody of the first or the second embodiment, and said method is particularly useful.

Problems solved by technology

However, a lot of problems are pointed out from the aspect of the effectiveness and the side effects such as bleeding.
However, since, according to the report by Sugiyama et al., the anti-human GPVI autoantibody purified from the patient's plasma has a function to induce platelet aggregation, it cannot be applied for medicaments immediately.
However, the method of producing industrially is not yet established.
However, compared with normal immunoglobulin that the cell produces, it generally possesses a low affinity to an antigen thereof and is short in the half-life in the vivo, too.
However, in all reports that have been published until now, no antibody having the activity to deplete GPVI on the platelet membrane without activating the platelet and / or without inducing thrombocytopenia in vivo has been disclosed.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-platelet membrane glycoprotein vi monoclonal antibody
  • Anti-platelet membrane glycoprotein vi monoclonal antibody
  • Anti-platelet membrane glycoprotein vi monoclonal antibody

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of GPVI Extracellular Region-Fc Fusion Protein

[0140]A. Preparation of Human GPVI Extracellular Region-Mouse Fc Fusion Protein (hGPVI-mFc)

(1) Construction of the Expression Plasmid for hGPVI-mFc Fusion Protein

[0141]Using mouse genomic DNA as a template, gene regions encoding respective domains of mouse immunoglobulin (mIgG2a) heavy chain constant region were amplified. That is, with the following primer pair, PCR reaction was performed. As a result, CH1 domain, hinge region, CH2 domain and CH3 domain were amplified with mIgG2a-a (SEQ ID NO: 152) and mIgG2a-c (SEQ ID NO: 154), mIgG2a-b (SEQ ID NO: 153) and mIgG2a-e (SEQ ID NO: 156), mIgG2a-d (SEQ ID NO: 155) and mIgG2a-g (SEQ ID NO: 158), and mIgG2a-f (SEQ ID NO: 157) and mIgG2a-h (SEQ ID NO: 159), respectively. Then these four amplified products were mixed, and PCR reaction using primers mIgG2a-a and mIgG2a-h was performed to obtain an amplified product, wherein respective domains were ligated (DNA fragment encoding heavy...

example 2

Preparation of Anti-GPVI Antibody

A. Preparation of Rabbit Polyclonal Antibody

[0146]To prepare a polyclonal antibody to human GPVI, rabbit was immunized. That is, 20 μg of hGPVI-mFc prepared in EXAMPLE 1A was diluted with 500 μl of saline and mixed with 500 μl of Freund complete adjuvant (DIFCO). Then, the mixture was subcutaneously administered to the dorsal of female New Zealand white rabbit (KITAYAMA LABES) whose weight was 2.1-2.2 kg. Two weeks later, once again, 20 μg of hGPVI-mFc was diluted with 500 μl of saline and mixed with 500 μl of Freund incomplete adjuvant (DIFCO). Then, the mixture was subcutaneously administered to the dorsal. One week after the completion of administration, the blood was collected from the ear vein, and according to the conventional method, anti-serum was isolated to purify an antibody. That is, to the anti-serum ammonium sulfate was added to make the final concentrations of saturated solution 33%. After stirring at 4° C. for one hour, the precipitat...

example 3

Group Classification of the Anti-GPVI Monoclonal Antibody

[0152]In order to classify the antibody obtained in EXAMPLE 2 by the binding property to GPVI, i.e. the difference of the binding region, using F1199, F1201, F1202, F1210 and F1211 antibodies, respectively, competitive assay was performed. Firstly, according to the method described by Nakane et al. (J. Histochem. Cytochem., 22, 1084, 1974), each peroxidase-labeled anti-GPVI monoclonal antibody was prepared.

[0153]Then, using the peroxidase-labeled antibody, competitive assay for respective purified antibodies. That is, hGPVI-hFc was diluted with D-PBS to 2 μg / mL, and the diluted solution was added to immunoplate (Maxisorp, NUNC) at 50 μL / well. After reaction at 37° C. for one hour, the well was washed five times with ion-exchanged water, and D-PBS containing 2% StabilGuard was added to each well for blocking. Then, 25 μL each of the above-mentioned labeled antibody and the purified antibody were added to the well and incubated ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Dissociation constantaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof:a) It specifically binds to human platelet membrane glycoprotein VI (GPVI);b) The function to activate a platelet and / or the function to induce a thrombocytopenia in vivo are low; andc) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.

Description

TECHNICAL FIELD[0001]The present invention relates to an antibody to human platelet membrane glycoprotein VI (hereinafter, sometimes abbreviated as GPVI) and a recognition region of the antibody.BACKGROUND ART[0002]The platelet plays a very important role in the clot formation and the biophylaxis, and its concerning in various clinical condition is being elucidated from the physiological role. In particular, it is remarkable about the function that the platelet forms a hemostatic plug. For example, when the vascular endothelial cell suffers damage, the collagen that is the major matrix protein of the subcutaneous vascular endothelium is exposed and the platelet adheres thereto. Next, the platelet is activated by the signal from the collagen and when finally, the platelet agglutinates through the fibrinogen. Then, since this fact causes morbidity such as thromboembolic disease depending on the situation, it is remarkable as a target for therapy.[0003]In the past, for the purpose of t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395C07K16/18C12N5/06C07K14/00A61P43/00G01N33/566C12N15/11C12P21/04C12N5/07C12N5/071
CPCA61K2039/505C07K16/2803C07K2316/96C07K2317/24C07K2317/54C07K2317/55C07K16/28C07K2317/565C07K2317/92C07K2319/30C07K16/34C07K2317/34C07K2317/56C07K2317/75C07K2317/76A61P43/00A61P7/02
Inventor TAKAYAMA, HIROSHISHIRAKAWA, KAMONFURUSAKO, SHOJIHOSAKA, YOSHITAKAMATSUSUE, TOMOKAZUNAITOH, KATSUKIHOTTA, YUMIKAWAHARA, TETSUSHI
Owner MOCHIDA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com